HOME >> MEDICINE >> NEWS
Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Tibotec Therapeutics announces initiation of the largest U.S. clinical study examining HIV treatment in treatment-experienced adult women

GRACE trial to explore gender-related differences in response to PREZISTA-based HIV therapy

Bridgewater, NJ, [Thursday, September 28, 2006] -- Tibotec Therapeutics Clinical Affairs, a division of Ortho Biotech Clinical Affairs, LLC, announced today the initiation of the largest clinical study conducted to date in treatment-experienced adult women with HIV to evaluate gender differences in response to an HIV medication.

GRACE (Gender, Race And Clinical Experience), a multi-center, open-label Phase IIIb trial, will compare gender differences in the efficacy, safety and tolerability of PREZISTA (darunavir) tablets administered with other antiretroviral agents over a 48-week treatment period. The study also will explore racial differences in treatment outcomes.

PREZISTA, co-administered with 100 mg ritonavir (PREZISTA/rtv) and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor. PREZISTA received accelerated approval based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled analysis of the TMC114-C213 (POWER 1) and TMC114-C202 (POWER 2) studies. Longer-term data will be required before the FDA can consider traditional approval for PREZISTA (see the full indication and important safety information below).

There is an urgent need to conduct clinical trials designed specifically for women with HIV. The ratio of women to men among Americans diagnosed with HIV has grown substantially since the HIV epidemic first emerged.

Today, women account for almost 30 percent of new HIV diagnoses in the U.S., and rates of HIV infection are particularly high among
'"/>

Contact: Pamela Van Houten
908-541-4137
Edelman Public Relations
28-Sep-2006


Page: 1 2 3 4 5

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. AstraZeneca announces SYMBICORT is now available in the US
3. Weill Cornell Medical College announces gifts totaling $400M
4. GSK announces launch of largest ever Phase III trial in lung cancer treatment
5. Elsevier announces launch of Brain Stimulation
6. NSW Premier announces $15M for childrens cancer research
7. National Inventors Hall of Fame announces 2007 inductees
8. Emory University announces new Global Health Institute
9. BioMed Central announces Journal of Medical Case Reports
10. Wiley announces partnership with NASPGHAN and AASLD
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:5/26/2015)... Beginning this fall, Boston University will ... Master of Social Work (MSW) program . Already available ... River Campus, the online option will be offered starting ... option is open to applicants holding an undergraduate social ... Education. Students entering the program will be granted 22 ...
(Date:5/26/2015)... Dearborn Ear, Nose & Throat in Dearborn, MI ... and improved website to better showcase their Detroit area ... Nose & Throat’s new website utilizes an innovative and ... seamlessly on any desktop computer, tablet or mobile device. ... Nose & Throat website include an innovative design ...
(Date:5/25/2015)... 2015 The report “Liver Failure ... on the therapeutic development for Liver Failure. The ... and MOAs to produce first-in-class and best-in-class products. ... Liver Failure with 22 market data tables and ... at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html . , Companies discussed ...
(Date:5/25/2015)... (PRWEB) May 26, 2015 Author Vincent N. ... of people today are overweight, and many of them aren’t ... He also knows that most people don’t realize the dangers ... hazards and man-made toxins that exist. There is ... realize exactly how serious tobacco is.” , In “ A ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into its ... recognized with this prestigious distinction for leadership in dentistry. ... professional women, boasting more than 700,000 members and over ... welcome Laquanis into this exceptional group of professional women,” ...
Breaking Medicine News(10 mins):Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 2Health News:Boston University to Offer Online Master of Social Work Advanced Standing Option 3Health News:Dearborn Ear, Nose & Throat Launches ‘Responsive Design’ Website 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
(Date:5/22/2015)... -- The Mesothelioma Victims Center is incredibly passionate about ... best possible compensation, and they are also extremely focused ... caused by exposure to asbestos or their family ... options such as a recent possible medical breakthrough. For ... anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
Breaking Medicine Technology:RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 52015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2
Cached News: